Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Intermountain Health Care, Inc.
With
NuView Diagnostics
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects with prostate cancer
Males 18-80 years of age
Biopsy-confirmed prostate cancer
Scheduled within 2 weeks for prostatectomy
Signed informed consent
Males 18-80 years of age
Diagnosis of BPH made by clinical symptoms (e.g., enlarged prostate, dribbling urine stream, frequent and urgent urination)
Scheduled within 2 weeks for TURP
Signed informed consent
Males or females 18-80 years of age
Diagnosed with bladder/kidney stones
Scheduled within 2 weeks for cystoscopy
Signed informed consent
You may not be if
Presence or history of another cancer diagnosis, with the exception of certain skin cancers
Currently treated with finasteride (Proscar®, Propecia®), dutasteride (Avodart®) or anti-androgen therapy (Lupron®)
Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Subjects with benign prostatic hypertrophy
Presence or history of any cancer diagnosis, with the exception of certain skin cancers
Currently treated with finasteride (Proscar®, Propecia®) or dutasteride (Avodart®)
Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Subjects with bladder/kidney stones
Presence or history of any cancer diagnosis, with the exception of certain skin cancers
Participated in a clinical study with an investigational drug within 2 weeks of the screening visit.
Clareo Health | Evaluation of the NV-VPAC1 Prostate Cancer (PCa) Urine Diagnostic Test in Subjects With Biopsy-confirmed Prostate Cancer, Benign Prostatic Hypertrophy, or Bladder/Kidney Stones.
